Argent Advisors Inc. Has $3.65 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Argent Advisors Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,543 shares of the company’s stock after purchasing an additional 771 shares during the quarter. Johnson & Johnson makes up 2.1% of Argent Advisors Inc.’s portfolio, making the stock its 10th largest holding. Argent Advisors Inc.’s holdings in Johnson & Johnson were worth $3,647,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. American Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 2.1% during the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after acquiring an additional 57 shares during the last quarter. Taylor & Morgan Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after acquiring an additional 57 shares during the last quarter. Circle Wealth Management LLC lifted its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock valued at $2,007,000 after acquiring an additional 59 shares during the last quarter. Argus Investors Counsel Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after acquiring an additional 61 shares during the last quarter. Finally, Alta Capital Management LLC lifted its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after acquiring an additional 61 shares during the last quarter. 68.59% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.6 %

Johnson & Johnson stock opened at $173.46 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company has a market capitalization of $453.51 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 3.35 and a beta of 0.57. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company’s fifty day moving average price is $167.44 and its two-hundred day moving average price is $171.39.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.60 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has authorized a stock buyback plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.61%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s payout ratio is 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The disclosure for this sale can be found here. Insiders have sold 118,795 shares of company stock valued at $20,230,174 over the last three months. 0.35% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Barclays began coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. Morgan Stanley cut their target price on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. UBS Group cut their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Finally, Bank of America cut their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $184.25.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.